Dr. Devin James Woelzlein, MD

Dr. Woelzlein practices at Bronson Methodist Hospital in Kalamazoo, Michigan, part of Bronson Healthcare Group.

Dr. Woelzlein's NPI, 1801056544, was assigned on June 16, 2008. Dr. Woelzlein graduated from Wayne State University School of Medicine in 2008. Dr. Woelzlein holds Michigan license 4301092476.

Dr. Woelzlein's primary practice is Bronson Methodist Hospital, at 601 John Street, Kalamazoo, MI 49007 in Kalamazoo County. The practice phone is (269) 341-6000.

Dr. Woelzlein's primary practice is Bronson Methodist Hospital in Kalamazoo, Michigan, part of Bronson Healthcare Group. Dr. Woelzlein is also affiliated with Bronson Battle Creek Hospital. The medical group on file is Bronson Medical Group. Dmand AI also links Dr. Woelzlein to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Woelzlein practices, 6 sites in all. Vendor and product names are available with a free account.

Emergency medicine is Dr. Woelzlein's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Dr. Woelzlein is licensed in Michigan.

CMS data shows 522 Medicare services from Dr. Woelzlein across 4 procedure codes in 2024, for 355 Medicare patients. Medicare paid $46,354 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 355 Medicare patients who saw Dr. Woelzlein in 2024. The largest group is 65 to 74, with 116 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 30% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Woelzlein's median patient age at 54, with 54% women.

In 2024, Dr. Woelzlein wrote 383 Medicare Part D claims for 256 patients. 93% of them were for generic drugs. CMS names the drug for 247 of them, across 9 drugs with 11 or more claims each, at $1,928 in total drug cost. In 2023, CMS named 190 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Woelzlein for performance year 2024, reported as part of a group. Dr. Woelzlein accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to Dr. Woelzlein from 1 drug or device company in 2024. Food and beverage make up the largest share, 100% of the total. Smith & Nephew, Inc. paid the most, $33.

Dr. Woelzlein graduated from Wayne State University School of Medicine in 2008.